Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines

The killed bivalent (O1 and O139) whole cell oral cholera vaccine (OCV) (Shanchol™) was first licensed in India in 2009 and World Health Organization pre-qualified in 2011. We assessed the safety and immunogenicity of this OCV in the Philippines. This was a phase IV, single-arm, descriptive, open-la...

Full description

Bibliographic Details
Main Authors: Maria Rosario Z. Capeding, Maria Liza Antoinette M. Gonzales, Mandeep Singh Dhingra, Naveena Aloysia D'Cor, Venkat Jayanth Midde, Badri Narayan Patnaik, Yaël Thollot, Eric Desauziers
Format: Article
Language:English
Published: Taylor & Francis Group 2017-10-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cholera vaccine
immunogenicity
shanchol
safety
the philippines
Online Access:http://dx.doi.org/10.1080/21645515.2017.1342908

Internet

http://dx.doi.org/10.1080/21645515.2017.1342908

Similar Items